Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab
Abstract Although several prognostic factors in nivolumab therapy have been reported in recurrent or metastatic head and neck cancer (RM-HNC) patients, these factors remain controversial. Here, we conducted a multicenter retrospective cohort study to investigate the impact of clinico-hematological f...
Saved in:
Main Authors: | Kiyoshi Minohara, Takuma Matoba, Daisuke Kawakita, Gaku Takano, Keisuke Oguri, Akihiro Murashima, Kazuhiro Nakai, Sho Iwaki, Wataru Hojo, Ayano Matsumura, Shinya Ozaki, Taijiro Ozawa, Ikuma Harata, Nobukazu Tanaka, Shinichiro Maseki, Hiroshi Tsuge, Sae Imaizumi, Shoji Mitsuya, Kazuho Moribe, Shinichi Esaki, Shinichi Iwasaki |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/83aafb03d05a4f159e72936107a43a7e |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
by: Nobukazu Fujimoto, et al.
Published: (2021) -
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
by: Alexander N Shoushtari, et al.
Published: (2021) -
Nivolumab-Induced Exocrine Pancreatic Insufficiency
by: Boudewijn Sweep, et al.
Published: (2021) -
MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
by: Katsuhiro Yoshimura, MD, PhD, et al.
Published: (2021) -
Use of nivolumab for colon cancer with Lynch syndrome
by: G. A. Khakimov, et al.
Published: (2020)